Can remarkable science be turned into mass-market products, asks David Crow. Cell therapies to treat blood cancers offer hope to patients who have exhausted all other possibilities and are likely to get regulatory approval this year. But they are expensive and production is time consuming, says David. The process needs to be streamlined and capacity matched to demand.
令人矚目的科學突破最終能轉化為滿足大眾市場需求的醫療產品嗎？治療血液癌癥的細胞療法為四處碰壁的患者提供了新的希望，并有望在今年內獲得監管批準。但它不僅成本高昂，生產也非常耗時……